Hook & thesis
Encore Capital Group (ECPG) is a specialty finance/receivables buyer that looks positioned to outperform in the current U.S. credit backdrop. Collections and purchased portfolio economics tend to improve when higher interest rates expand net yields and consumer delinquencies remain elevated but stable. At a current price of $98.44 and a market capitalization roughly $2.09 billion, Encore trades at a low-teens multiple of cash flow and under 8.5x on an EV/EBITDA basis, leaving room for near-term upside if collections and portfolio acquisitions continue at recent run rates.
My trade thesis: buy ECPG mid term (45 trading days) around $98.44. The company has continued to execute on liability management, recent portfolio purchases generated strong collections historically, and the stock’s valuation (P/E ~6.9; EV/EBITDA ~8.16) does not fully reflect upside from a sustained favorable U.S. credit environment. Manageable entry, tight stop and a sensible target make this an actionable trade with defined risk.
What Encore does and why the market should care
Encore is an international specialty finance company primarily focused on debt recovery solutions. Its largest franchise is the U.S., where the company buys charged-off consumer receivables and collects through a mix of in-house collections and litigation. The business is highly levered to two fundamentals: the price/quality of portfolios the company can buy and the efficiency of its collection engine.
Why the market should care now: higher interest rates and sticky consumer credit stress widen spreads on new portfolio buys and improve yield on existing portfolios. Encore’s U.S. operations have been a big driver of recent performance; management has also cleaned up near-term maturities through sizable note offerings which reduces refinancing risk and improves funding optionality.
Supporting numbers
- Current price: $98.44.
- Market cap: approximately $2.09 billion.
- EPS (TTM): $14.22, producing a P/E of roughly 6.9x.
- Price-to-book: ~1.93x; return on equity: ~27.96%.
- Debt to equity: elevated at ~3.87x, which explains a higher enterprise valuation relative to market cap; enterprise value is about $6.08 billion.
- EV/EBITDA: ~8.16x; free cash flow: ~$125.1 million.
- 52-week range: $39.95 - $104.98, illustrating how cyclical and sentiment-driven the stock is.
- Short interest is meaningful but manageable: roughly 1.28 million shares on a float of ~20.18 million (days to cover ~3.23).
Recent execution - why I trust the setup
Encore has been actively managing its liability profile. Earlier in the year the company priced multiple senior secured notes - including a $750 million 6.625% 2032 offering and an upsized 325 million 2033 floating-rate offering - and used proceeds to redeem portions of higher-cost or near-term maturities. Those moves reduce near-term refinancing pressure and lock in committed funding to support portfolio purchases.
Operationally, Q2 2025 reported an 86% jump in EPS year-over-year, driven by record portfolio purchases and collections in the U.S. That demonstrates the levered upside: when acquisitions and collections line up, earnings and cash flow can move materially. Put another way, Encore’s economics meaningfully benefit from even modest improvement in purchased portfolio yields and collection rates.
Valuation framing
At a market cap near $2.09 billion and enterprise value around $6.08 billion, Encore’s capital structure is highly levered, which is typical for the sector. The company’s P/E of ~6.9x is compressive but not without cause given leverage and the cyclicality of recoveries. EV/EBITDA near 8.16x and price-to-free-cash-flow ~16.68x suggest the stock is attractively priced relative to the returns that can be generated from disciplined portfolio purchases and steady collections.
Qualitatively, valuation looks compelling if: 1) U.S. collections remain resilient, 2) the company keeps funding costs under control via liability management, and 3) portfolio prices remain favorable. If those conditions persist, a re-rating toward mid-teens EV/EBITDA would be plausible; even absent a re-rating, incremental multiple expansion combined with continued strong cash generation supports the mid-term upside proposed below.
Catalysts (2-5)
- Continued strong U.S. collections and portfolio economics reported in the next quarterly update; directionally similar to the Q2 2025 beat where EPS jumped 86%.
- Further liability management or successful refinancing that reduces average funding costs and extends maturities.
- Accelerated accretive portfolio purchases at attractive yields that boost near-term cash flow.
- Macro stability or any incremental deterioration in consumer credit that is still priced attractively into portfolio acquisitions (paradoxically, some stress can be an acquisition opportunity if priced correctly).
Trade plan (actionable)
Direction: Long ECPG
Entry: $98.44
Stop loss: $88.00
Target: $110.00
Horizon: mid term (45 trading days). I expect this trade to play out over roughly 45 trading days because catalysts (quarterly updates, continued collections data, and the market digesting liability-management benefits) typically resolve within one to three months. This horizon gives time for re-rating and for collections momentum—or quarter-end disclosures—to show through to earnings and cash flow.
Rationale for levels: entry is close to the current market price, the stop under $88 protects against a deterioration in collections or an outsized macro sell-off (it sits well below recent moving averages and would indicate a momentum break). The $110 target is slightly above the 52-week high ($104.98) and captures a reasonable re-rating to multiple expansion plus incremental earnings improvement (roughly 10-12% upside from entry). Risk/reward at these levels is favorable if the company continues to execute and U.S. credit conditions remain supportive.
Risks & counterarguments
- Macro shock to consumer credit: A sharp, rapid deterioration in U.S. consumer credit could push collection rates lower and force portfolio write-downs, compressing margins. Given Encore’s leverage (debt-to-equity ~3.87x), such a shock would hit NAV and earnings quickly.
- Funding risk despite liability management: Even though management has executed several note offerings to push out maturities and reduce near-term interest risk, a higher-for-longer rate environment or dislocation in capital markets could raise funding costs unexpectedly or limit appetite for further issuance.
- Regulatory and litigation risk: The collections industry periodically faces regulatory scrutiny. New rules or increased litigation expenses could raise operating costs and reduce realized recoveries.
- Portfolio pricing competition: If other buyers bid aggressively for charged-off receivables, Encore may face higher acquisition prices that compress future yields and ROIC on new purchases.
- Counterargument: One could argue Encore is already priced fairly given its capital structure and cyclical earnings; a modest miss in collections or a single quarter of slower portfolio placements could erase short-term gains. Also, the company’s elevated leverage is a structural constraint that limits how far valuation can rerate without continued earnings outperformance.
What would change my mind
I would revise or exit this stance if any of the following occur: 1) a material deterioration in U.S. collections metrics is reported (collections materially below consensus), 2) funding markets tighten and Encore cannot refinance on reasonable terms or misses a covenant, 3) regulatory actions that meaningfully increase compliance costs or restrict collection practices, or 4) management signals a pullback in disciplined portfolio purchasing that would slow future organic growth.
Conclusion
Encore Capital is a cyclical, levered play on U.S. consumer credit recoveries and disciplined portfolio economics. At $98.44, the stock trades at a modest multiple to earnings and an EV/EBITDA that leaves room for upside should collections and purchases keep pace with recent execution. The company’s active liability-management moves lower refinancing risk and give the story some defensive characteristics despite high leverage.
For the mid-term trader willing to accept the industry-specific risks and leverage dynamics, ECPG offers a pragmatic entry: buy at $98.44, stop at $88.00, and target $110.00 over about 45 trading days. Keep a close eye on collections print and any changes in funding spreads; those are the two items most likely to change this view.